Clinical Trials
We are getting really busy with the Clinical Trials and over the next few months we will be recruiting for quite a few Scleroderma and Pulmonary Hypertension studies. We are also expanding and will soon have a second Clinical trials nurse as well as the support of the specialist nurses who are also experienced in clinical trials.
Future trials:
We are currently recruiting patients for two Scleroderma studies which are due to start in the near future:
P144:
A trial to evaluate the efficacy and safety of the topical application of the drug ‘P144’ for skin fibrosis in patients with Systemic Sclerosis.
Novartis Study: A trial to evaluate the efficacy and safety of an oral dose of ST1571 for diffuse patients with fibrosis.
We are also currently recruiting for a Pulmonary Hypertension study which is also due to start soon:
FREEDOM: The purpose of this study is to test oral Treprostinil in the treatment of Pulmonary Hypertension.
Ongoing Trials:
SSTEP: This is a five year trial, which started in 2002, looking at the use of Iloprost tablets in lowering the incidence of heart attacks, angina and strokes.
ARIES: A trial looking at the drug Ambrisentan in slowing down the progression of Pulmonary Arterial Hypertension.
RAPIDS-2: A trial looking at the use of the study drug Bosentan alongside a placebo for patients with digital ulcers.
Tadelafil: This study looks into the safety and efficacy of the drug Taldelafil in decreasing the symptoms of Pulmonary Hypertension.
TRIUMPH:
The purpose of this study is to test inhaled Treprostinil in the treatment of Pulmonary Hypertension.
Completed trials:
MQX-503: This was a Raynauds trial involving a topical gel formation of Nitroglycerine MQX-503, and matching placebo, to prevent Raynauds Phenomenon. This trial ended in February 2007 and we await the trial results.
ASSET 1 & 2: A trial that looked at the treatment of Pulmonary Hypertension in patients with Sickle cell, with the drug Bosentan. This trial ended in 2007.
STRIDE: A study to evaluate the long-term safety of the drug Sitaxsentan compared to Bosentan in patients with Pulmonary Arterial Hypertension. This trial is complete and Sitaxsentan has been licensed.
If you are interested in taking part in future trials, please contact
Rachel on 020 7317 7544